Citation Impact
Citing Papers
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
2014 Standout
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
2011 Standout
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
2005 StandoutScience
Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
2010
Multiple myeloma associated with diffuse osteosclerotic bone lesions: A clinical entity distinct from osteosclerotic myeloma (POEMS syndrome)
1997
Amyloidosis
1994
Mechanisms, regulation and functions of the unfolded protein response
2020 Standout
PROGNOSTIC FACTORS IN MULTIPLE MYELOMA
1999
The biology of human natural killer-cell subsets
2001 Standout
MYC on the Path to Cancer
2012 Standout
The Systemic Amyloidoses
1997 Standout
Clinical Course of Patients With Relapsed Multiple Myeloma
2004
High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma.
1994
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
1998 Standout
Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006
2010
THE ROLE OF INTERLEUKIN-1β IN THE PATHOGENESIS OF MULTIPLE MYELOMA
1999
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
1996 Standout
Role of Cardiac Magnetic Resonance Imaging in the Detection of Cardiac Amyloidosis
2010
The Hallmarks of Cancer
2000 Standout
Multiple myeloma
2000 Standout
The neural cell adhesion molecule NCAM in multiple myeloma
1996
Ontogeny and Expansion of Human Natural Killer Cells: Clinical Implications
2001
Super-Enhancers in the Control of Cell Identity and Disease
2013 Standout
Cytokine Expression in Multiple Myeloma and Monoclonal Gammopathy: Analysis by Reverse Transcription/Polymerase Chain Reaction and Quantitative PCR
1996
The biological and clinical significance of the KI‐67 growth fraction in multiple myeloma
1992
Guideline of transthyretin-related hereditary amyloidosis for clinicians
2013 Standout
Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component
2009
Protein folding and misfolding
2003 StandoutNature
Four structural risk factors identify most fibril-forming kappa light chains
2000
Immunity, Inflammation, and Cancer
2010 Standout
Primary systemic amyloidosis presenting as giant cell arteritis and polymyalgia rheumatica
1994
Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation
2001
Antibody-Mediated Resolution of Light Chain-Associated Amyloid Deposits
2000
Systemic amyloidosis
2015 Standout
High Serum Lactate Dehydrogenase Level as a Marker for Drug Resistance and Short Survival in Multiple Myeloma
1991
pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels
2014 Standout
Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants.
1997
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
2008
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
2003 Standout
Polymyalgia Rheumatica and Giant-Cell Arteritis
2002 Standout
Applications of machine learning in drug discovery and development
2019 Standout
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
1999 Standout
The Ki-67 protein: From the known and the unknown
2000 Standout
Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity
1990
Mechanisms of Bone Metastasis
2004 Standout
Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on Outcome
2011
Protein misfolding, evolution and disease
1999 Standout
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma.
1995
High-risk multiple myeloma treated with high-dose melphalan.
1992
Immunofluorescence Labeling Indices in Myeloma and Related Monoclonal Gammopathies
1987
The role of IL-6 and STAT3 in inflammation and cancer
2005 Standout
Increased serum levels of β2m‐free HLA class I heavy chain in multiple myeloma
1999
Molecular Mechanisms of Amyloidosis
2003 Standout
Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine only
1996
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
High-Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: Up-front or Rescue Treatment? Results of a Multicenter Sequential Randomized Clinical Trial
1998
Echocardiographic findings in systemic amyloidosis: Spectrum of cardiac involvement and relation to survival
1985
Response rates and survival in primary systemic amyloidosis
1991
Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma [see comments]
1996
Identification of Predictors of Disease Status and Progression in Patients with Myeloma (MM)
2000
Interleukin-6 and the acute phase response
1990 Standout
Circulating Ki67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy.
1995
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
2011 Standout
New drug therapy of amyloidoses: resorption of AL-type deposits with 4'- iodo-4'-deoxydoxorubicin
1995
Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis
2004
Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis
2013
Infusion of Light Chains From Patients With Cardiac Amyloidosis Causes Diastolic Dysfunction in Isolated Mouse Hearts
2001
Cardiovascular Magnetic Resonance in Cardiac Amyloidosis
2005
Improved survival in multiple myeloma and the impact of novel therapies
2007 Standout
Autologous stem cell transplantation for primary systemic amyloidosis
2002
Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay
2010
High-Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: Up-front or Rescue Treatment? Results of a Multicenter Sequential Randomized Clinical Trial
1998
Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma
1996
A new staging system for multiple myeloma based on the number of S- phase plasma cells
1995
Plasmablastic Morphology—An Independent Prognostic Factor With Clinical and Laboratory Correlates: Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9486 Report by the ECOG Myeloma Laboratory Group
1998
Bortezomib: Proteasome Inhibition as an Effective Anticancer Therapy
2006
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
2002
Diverse karyotypic abnormalities of the c -myc locus associated with c -myc dysregulation and tumor progression in multiple myeloma
2000
High levels of interleukin-6 are associated with low tumor burden and low growth fraction in multiple myeloma
1994
Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma
1989
Autotransplants in multiple myeloma: what have we learned?
1996
Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321
2006
Multiple Myeloma
2011 Standout
Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors
1999
Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities
1995
International Staging System for Multiple Myeloma
2005 Standout
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
2006
Works of RA Kyle being referenced
Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma
1998
Monoclonal gammopathy of undetermined significance
1994
Clinical aspects of multiple myeloma and related disorders including amyloidosis.
1999
High-dose therapy in multiple myeloma and primary amyloidosis: an overview.
1999
Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma
1988
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma [see comments]
1993
Why better prognostic factors for multiple myeloma are needed [editorial] [see comments]
1994
Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases
1986